Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Malignant melanoma is a highly aggressive and metastatic skin cancer characterized by tyrosinase overexpression. Therefore, harnessing the activation of tyrosinase-catalyzed toxicity enables targeted tumor-specific therapy while sparing surrounding healthy tissues. Herein, an AND logic-gated, cyanobacteria (Cyan)-driven, living therapeutic alginate hydrogel is proposed that activates the tyrosinase-catalyzed ferroptotic phenolic prodrug N-(4-hydroxyphenyl) acetamide (APhH), triggering cascaded reactive oxygen species (ROS) generation and glutathione (GSH) depletion for melanoma-specific ferroptosis. The therapeutic mechanism operates through a sequential dual-input procedure: microorganism-driven photosynthetic oxygenation and endogenous tyrosinase catalysis. Light-activated Cyan performs photosynthetic oxygen production, alleviating tumor hypoxia while acting as the essential cofactor for tyrosinase. Once activated, tyrosinase catalyzes the conversion of APhH into the cytotoxic benzoquinone derivative, 4-acetamido-o-benzoquinone (APhQ). Concurrently, oxygen is transformed into ROS, synergizing with APhQ to deplete GSH for glutathione peroxidase 4 inactivation, thereby promoting lipid peroxide generation. The combined effects of ROS generation, GSH depletion, and lipid peroxide accumulation culminate in a potent ferroptotic response, selectively targeting melanoma cells while sparing healthy tissue. This study highlights the potential of an AND logic-gated approach for achieving highly specific, targeted prodrug activation, enhancing precision in melanoma treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.202502969DOI Listing

Publication Analysis

Top Keywords

melanoma treatment
8
photosynthetic oxygenation
8
ros generation
8
gsh depletion
8
lipid peroxide
8
logic gate
4
gate strategy
4
strategy targeted
4
melanoma
4
targeted melanoma
4

Similar Publications

A new frontier in oncology: Understanding the landscape of cancer vaccines.

J Oncol Pharm Pract

September 2025

Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.

Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF

Background: Mohs micrographic surgery (MMS) allows for precise excision of skin cancers with intraoperative histologic margin assessment. Incidental findings-unexpected histopathologic features unrelated to the primary lesion-are occasionally discovered but scantily characterized in the literature.

Objective: To systematically review published cases of incidental histologic findings identified during MMS, with attention to their frequency, clinical implications, and management.

View Article and Find Full Text PDF

Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.

View Article and Find Full Text PDF

This is a case of drug-induced liver injury (DILI) in a 75-year-old male patient with a history of metastatic melanoma, who initially presented with a syncopal episode causing a fall. Following stabilization in the emergency department (ED), the patient was found to have bilateral subdural hematomas, and later an MRI showed evidence of metastatic lesions in the brain with hemorrhagic conversion. These findings led to a prolonged inpatient stay in the intensive care unit and eventual development of pneumonitis, which was subsequently treated with hepatotoxic antibiotics despite initial labs showing mildly elevated liver enzymes.

View Article and Find Full Text PDF